Restart Life Stock Price, News & Analysis

Wellbeing Digital Sciences Inc. (OTC: KONEF) announces the recruitment of participants for a pioneering clinical trial examining the effects of psilocybin on adults with fragile X syndrome (FXS). Conducted by its subsidiary KGK Sciences, the 28-day Phase IIA study is the first authorized by Health Canada allowing take-home psilocybin dosing. The study, set to treat its first participant in Q2 2023, aims to evaluate the safety and efficacy of Nova Mentis’ psilocybin drug (NM-1001) in a controlled environment, using advanced diagnostic technologies. Preliminary results are expected later this year, highlighting significant potential for psilocybin therapy in addressing unmet medical needs related to FXS.

Wellbeing Digital Sciences Inc. (KONEF, NMLSF) has announced that its subsidiary, KGK Sciences Inc., gained IRB approval in Canada to conduct a groundbreaking Phase IIA clinical trial. This study will test the efficacy of psilocybin on adults with fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder (ASD). The trial is part of a partnership with Nova Mentis Life Science Corp., aiming to assess psilocybin's impact on cognitive and behavioral symptoms. Patient recruitment is expected to begin this year. Notably, Health Canada has granted special permission for participants to take the drug home, marking a significant milestone in clinical research. This trial supports Nova's ongoing efforts to improve treatment options for FXS patients, following their FDA Orphan Drug designation received in 2021.

Wellbeing Digital Sciences Inc. (KONEF, NMLSF) announces its subsidiary, KGK Sciences, has received a Section 56 exemption to proceed with a Phase IIA clinical trial evaluating microdose psilocybin therapy for fragile X syndrome (FXS). This trial aims to study cognitive and behavioral symptoms linked to FXS, a major genetic cause of autism spectrum disorder. The study is significant as it represents a pioneering approach in this area, supported by a No Objection Letter from Health Canada. With the production of cGMP synthetic psilocybin underway, the trial seeks to enhance understanding of psilocybin's therapeutic potential, with participant recruitment starting in early 2023.

Wellbeing Digital Sciences Inc. has announced that its subsidiary KGK Sciences has received approval from Health Canada for a Phase II clinical trial. The study will assess the efficacy of psilocybin therapy on Fragile X syndrome, a leading genetic cause of autism spectrum disorder. The open-label trial aims to recruit 10 participants and is set to begin recruiting in early 2023. The results will support Nova Mentis Life Science Corp.’s drug development program, which has FDA Orphan Drug designation.

Wellbeing Digital Sciences Inc. has announced that its subsidiary KGK Sciences submitted a clinical trial application for a Phase IIa study testing the efficacy of psilocybin in treating cognitive and behavioral symptoms associated with Fragile X Syndrome (FXS). The trial, sponsored by Nova Mentis Life Science Corp., will assess a 1.5 mg microdose of psilocybin and is expected to begin in early 2023 pending Health Canada's approval. This study marks a significant milestone as the first human trial using psilocybin for FXS.

Wellbeing Digital Sciences (OTC: KONEF, NEO: MEDI) announced that its subsidiary KGK Science will conduct a Phase II clinical trial to evaluate the effects of psilocybin on Fragile X syndrome. This marks the first research into psilocybin microdoses for improving behavioral and cognitive symptoms associated with the disorder. The trial, which will involve 10 participants, supports Nova Mentis’ drug development efforts under FDA Orphan Drug designation. Results are aimed at addressing significant unmet medical needs in treatment.

Nova Mentis Life Science Corp. has initiated patient enrollment for its North American Observational Study focusing on Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS). This study aims to develop a Diagnostic Index to enhance diagnosis and treatment of these conditions by analyzing neuroinflammatory profiles and serotonin levels in patients. The company plans to recruit at least 300 participants, including 200+ patients with ASD/FXS. Additionally, Nova has engaged consulting firms for marketing services and issued 1,250,000 stock options to marketing consultants.

Nova Mentis Life Science Corp. has completed a non-brokered private placement financing, raising $1,483,500. The company issued 29,670,000 units at CAD $0.05 each, with each unit including one common share and one warrant priced at CAD $0.075. Proceeds will fund the launch of an autism spectrum disorder observational study and a Phase 2A clinical study for fragile X syndrome, along with general working capital. All issued securities are subject to a four-month hold period.

Nova Mentis Life Science Corp. (NMLSF) announced successful results from a preclinical study on psilocybin microdoses for treating fragile X syndrome (FXS). Conducted at Rome Tre University, the study demonstrated that low doses of psilocybin improved cognitive defects in a genetic model of FXS, with the optimal dose being 0.1 mg/kg. The findings support advancing to a Phase 2A clinical trial in Canada. Additionally, Nova plans to raise up to $1 million through a private placement to fund these initiatives.